Physicochemical Properties
| Molecular Formula | C56H70N10O15 |
| Molecular Weight | 1123.21301412582 |
| Exact Mass | 1062.481 |
| CAS # | 676367-27-4 |
| Related CAS # | Chemerin-9 (149-157) (TFA) |
| PubChem CID | 11332190 |
| Appearance | Typically exists as solid at room temperature |
| LogP | -1.3 |
| Hydrogen Bond Donor Count | 12 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 28 |
| Heavy Atom Count | 77 |
| Complexity | 2000 |
| Defined Atom Stereocenter Count | 8 |
| SMILES | C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)N |
| InChi Key | QLVGSBXIQFERFK-NBBYSTNSSA-N |
| InChi Code | InChI=1S/C54H66N10O13/c1-32(47(69)60-41(28-34-14-7-3-8-15-34)51(73)63-43(31-65)54(76)77)58-50(72)40(27-33-12-5-2-6-13-33)61-49(71)39(23-24-45(56)67)59-46(68)30-57-52(74)44-18-11-25-64(44)53(75)42(29-35-16-9-4-10-17-35)62-48(70)38(55)26-36-19-21-37(66)22-20-36/h2-10,12-17,19-22,32,38-44,65-66H,11,18,23-31,55H2,1H3,(H2,56,67)(H,57,74)(H,58,72)(H,59,68)(H,60,69)(H,61,71)(H,62,70)(H,63,73)(H,76,77)/t32-,38-,39-,40-,41-,42-,43-,44-/m0/s1 |
| Chemical Name | (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Chemerin-9 (149-157) (0.1 nM; 24 hours; cardiac fibroblasts) increases cardiac fibroblast migration and stimulates phosphorylation of Akt and ERK and ROS generation [4]. |
| ln Vivo | In PDM mice, chemerin-9 (149–157) (0.2 mg/kg; i.p.; daily for 42 days) decreases glucose intolerance and IR [1]. Chemerin-9 (149–157) (7.7 μg/kg; ih; daily for 28 days) protects the abdominal aorta from MMP injury and exhibits anti-inflammatory and anti-angiogenic properties in ApoE–/– mice[2]. Aβ1-42-induced memory impairment is ameliorated by Chemerin-9 (149-157) (8 μg/kg; ICV; daily; for 14 days; male Kunming mice) [3]. |
| Cell Assay |
Western Blot Analysis[4] Cell Types: Cardiac Fibroblasts Tested Concentrations: 0.1 nM Incubation Duration: 24 hrs (hours) Experimental Results: Phosphorylation of Akt and ERK was stimulated. |
| Animal Protocol |
Animal/Disease Models: PDM mice [1] Doses: 0.2 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 42 days Experimental Results: The expression of chemerin, GLUT2 and PDX1 increased, thereby alleviating the glucose tolerance of PDM model mice Insomnia and IR. Animal/Disease Models: ApoE-/- mice [2] Doses: 7.7 μg/kg Route of Administration: subcutaneous injection; one time/day for 28 days Experimental Results: Inhibited abdominal aortic dilation and reversed SMC loss. Animal/Disease Models: ApoE-/- mice [2] Doses: 7.7 μg/kg Route of Administration: subcutaneous injection; one time/day for 28 days. Experimental Results: Down-regulated the expression of MMP2 and MMP-9, and diminished the levels of chemerin and CMKLR1. Animal/Disease Models: Male Kunming mice [3] Doses: 8 μg/kg Route of Administration: intracerebroventricular injection; daily; for 14 days Experimental Results: Increased levels of pro-inflammatory cytokines in the hippocampus, such as interleukin 1β (IL -1β), tumor necrosis factor (TNF-α), and interleukin 6 (IL-6). |
| References |
[1]. Regulatory effect of chemerin and therapeutic efficacy of chemerin 9 in pancreatogenic diabetes mellitus. Mol Med Rep. 2020 Mar;21(3):981-988. [2]. Chemerin-9 Attenuates Experimental Abdominal Aortic Aneurysm Formation in ApoE-/- Mice. J Oncol. 2021 Apr 17;2021:6629204. [3]. Chemerin-9 Peptide Enhances Memory and Ameliorates Aβ1-42-Induced Object Memory Impairment in Mice. Biol Pharm Bull. 2020 Feb 1;43(2):272-283. [4]. Chemerin-9 stimulates migration in rat cardiac fibroblasts in vitro. Eur J Pharmacol. 2021 Dec 5;912:174566. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8903 mL | 4.4515 mL | 8.9031 mL | |
| 5 mM | 0.1781 mL | 0.8903 mL | 1.7806 mL | |
| 10 mM | 0.0890 mL | 0.4452 mL | 0.8903 mL |